JAK inhibition for the early treatment of myelofibrosis

Ruben Mesa, MD, Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses real-world data and data from long-term follow-up studies on survival outcomes for patients with myelofibrosis treated with JAK inhibitors, commenting on how early they should be incorporated in the treatment algorithm. Dr Mesa talks on the COMFORT-I (NCT00952289) and COMFORT-2 (NCT00934544) trials which have demonstrated a survival advantage in patients treated with the JAK2 inhibitor ruxolitinib. Additionally, Dr Mesa explains the NCCN approach to categorize low- to high-risk myelofibrosis as well as symptomatic and asymptomatic myelofibrosis, and how this may impact the use of JAK inhibitors in the future. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.